SCHEMBL1798674

SCHEMBL1798674

O=C(c1ccc(OC(F)(F)C(F)F)cc1)N1CCCC1CN1CCCC1

nearest known ligand 0.56

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
HRH3 Q9Y5N1 14/20 0.56
POLB P06746 1/20 0.48
MET P08581 1/20 0.47
KCNH2 Q12809 2/20 0.46
OPRD1 P41143 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1798672 1.00 HRH3 (0.56) HRH3POLBMETKCNH2OPRD1
SCHEMBL1795442 0.90 HRH3 (0.68) HRH3POLBMETKCNH2
SCHEMBL1795444 0.90 HRH3 (0.68) HRH3POLBMETKCNH2
SCHEMBL1799287 0.85 ALDH1A1 (0.54) HRH3POLBMET
SCHEMBL1799286 0.85 ALDH1A1 (0.54) HRH3POLBMET
SCHEMBL3278795 0.82 HRH3 (0.64) HRH3POLBMETKCNH2OPRD1
SCHEMBL3278791 0.82 HRH3 (0.64) HRH3POLBMETKCNH2OPRD1
SCHEMBL1799794 0.81 HRH3 (0.53) HRH3POLBMETKCNH2OPRD1
SCHEMBL1799792 0.81 HRH3 (0.53) HRH3POLBMETKCNH2OPRD1
SCHEMBL12615280 0.81 HRH3 (0.66) HRH3POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7951826-B2 Obesity; cognition activators; narcolepsy ELI LILLY AND COMPANY (US) 2011-05-31 US claimed
EP-1861360-B1 PYRROLIDINE DERIVATIVES AS HISTAMINE H3 RECEPTOR ANTAGONISTS LILLY CO ELI (US) 2009-12-02 EP claimed
US-20080207732-A1 Pyrrolidine Derivatives as Histamine H3 Receptor Antagonists ELI LILLY AND COMPANY 2008-08-28 US claimed
US-7951826-B2 Obesity; cognition activators; narcolepsy ELI LILLY AND COMPANY (US) 2011-05-31 US disclosed
US-7951826-B2 Obesity; cognition activators; narcolepsy ELI LILLY AND COMPANY (US) 2011-05-31 US disclosed
US-7951826-B2 Obesity; cognition activators; narcolepsy ELI LILLY AND COMPANY (US) 2011-05-31 US disclosed
EP-1861360-B1 PYRROLIDINE DERIVATIVES AS HISTAMINE H3 RECEPTOR ANTAGONISTS LILLY CO ELI (US) 2009-12-02 EP disclosed
EP-1861360-B1 PYRROLIDINE DERIVATIVES AS HISTAMINE H3 RECEPTOR ANTAGONISTS LILLY CO ELI (US) 2009-12-02 EP disclosed
US-20080207732-A1 Pyrrolidine Derivatives as Histamine H3 Receptor Antagonists ELI LILLY AND COMPANY 2008-08-28 US disclosed
US-20080207732-A1 Pyrrolidine Derivatives as Histamine H3 Receptor Antagonists ELI LILLY AND COMPANY 2008-08-28 US disclosed
US-20080207732-A1 Pyrrolidine Derivatives as Histamine H3 Receptor Antagonists ELI LILLY AND COMPANY 2008-08-28 US disclosed
EP-1861360-A1 PYRROLIDINE DERIVATIVES AS HISTAMINE H3 RECEPTOR ANTAGONISTS ELI LILLY AND COMPANY (US) 2007-12-05 EP disclosed
WO-2006101808-A1 PYRROLIDINE DERIVATIVES AS HISTAMINE H3 RECEPTOR ANTAGONISTS ELI LILLY AND COMPANY (US) 2006-09-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080207732-A1 Pyrrolidine Derivatives as Histamine H3 Receptor Antagonists HRH3, HCRTR1, HRH4 HRH3 1/4885POLB 2780/4885MET 1108/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.